160results about "Gastrointestinal cells" patented technology

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention discloses a perfusion-free parallel double-cell intestine-liver chip system and application thereof in drug uptake evaluation, and belongs to the field of biomedical engineering and organ chips. The chip disclosed by the invention is simple in structure, free of an external pump and a complex pipeline, capable of realizing fluid circulation through swinging, convenient to operate, low in cost and small in pollution risk, and also capable of promoting cell differentiation and optimizing hepatocyte functions. The chip integrates a parallel intestinal cell and a liver cell which are communicated through a shared channel, can continuously simulate intestinal absorption and liver first-pass metabolism, and is closer to an in-vivo physiological state. The device adopts a detachable transparent modular design, can be repeatedly used, supports multi-group parallel operation, can improve experimental flux and result repeatability, and is suitable for in-vitro verification of drug absorption, permeability and metabolism evaluation.

The present disclosure provides methods of making tissue-derived epithelial organoids. In particular, the present disclosure provides a tissue-derived epithelial organoid embedded in a hydrogel suspended in a culture medium. The present disclosure further provides methods of using such organoids.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

The invention discloses application of ceramide and a synthetic regulating agent thereof in regulating porcine epidemic diarrhea virus infection, and belongs to the technical field of biology. Experiments prove that the mRNA expression quantity and virus titer of PEDV (porcine epidemic diarrhea virus) in IPEC-J2 cells are remarkably improved by exogenously adding C24-ceramide or regulating and controlling the endogenous ceramide level through a ceramide enzyme inhibitor, and a ceramide synthesis inhibitor shows a remarkable antiviral effect. The invention proves that ceramide is a key factor for PEDV (porcine epidemic diarrhea virus) replication, and an inhibitor targeting a ceramide synthetic route can effectively inhibit PEDV infection, so that a theoretical basis and an experimental basis are provided for constructing a porcine epidemic diarrhea virus susceptibility model and developing a novel anti-PEDV drug.

The purpose of the present invention is to provide a novel method for culturing tissue-derived cells. The method uses a cell culture method including a step for co-culturing cells derived from the skin and at least one type of cell selected from among cells derived from the intestine, cells derived from the heart, cells derived from the brain, cells derived from the stomach, cells derived from the embryonic membrane, cells derived from the kidney, and cells derived from the lung. And culturing the skin-derived cells.

Disclosed herein are enteroids, obtained by dissociating an epithelial cell population from a non-transplanted human intestinal organoid (HIO), such as an HIO produced in vitro from human pluripotent stem cells (hPSCs). Also disclosed herein are methods of producing and using the same, including methods of transplantation involving said enteroids, particularly for treating a gastrointestinal disease or condition. Also disclosed herein are methods of transplantation involving HIOs and / or HIO components, particularly for treating a gastrointestinal disease or condition.

The invention relates to the technical field of biology, and discloses a construction method of a gastric cancer organoid culture system, which comprises the following steps: preparation of a conditioned medium: culturing L-WRN cells and collecting the conditioned medium; preparing a gastric cancer organoid culture medium, and mixing the conditioned culture medium, the basic culture medium, a plurality of growth factors and additives; and extraction and culture of organoid: separating cells from gastric cancer tissues, mixing the cells with matrigel, and culturing by using the prepared culture medium. According to the method, the repeatability and the stability of the organoid model are improved, the response consistency of the organoid in drug screening is improved, and the reliability of the model in disease mechanism research and personalized medical application is guaranteed.

The invention belongs to the technical field of biology, and discloses a preparation method of an intestinal plexus patch, which comprises the following steps: killing an intestinal tract donor, fixing intestinal tissue segments of duodenum, jejunum, ileum or colon by using paraformaldehyde, and dehydrating to obtain dehydrated intestinal tissue segments; washing the dehydrated intestinal tissue section and removing mesentery, fat and Pari's lymph nodes attached to the jejunum, cutting an intestinal mass of about 4-6mm perpendicular to the intestinal tissue section, flatly laying the intestinal mass on a glass slide, dropwise adding a PBS (Phosphate Buffer Solution) of Triton X-100, fixing the intestinal mass by using a smooth surface of a pair of tweezers, stripping muscle tissues along the annular muscle direction, and drying the intestinal mass in a drying oven. The intestinal slices with intermuscular nerve plexus are obtained; finally, the intestinal piece with the intermuscular nerve plexus is cleaned, then fluorescent staining and piece sealing are conducted, and the mouse intestinal nerve plexus patch is obtained. The preparation method of the mouse intestinal nerve plexus patch has the advantages of being convenient, rapid and the like.

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

Disclosed herein are improved in vitro methods of making splanchnic mesoderm cell types and subtypes thereof from pluripotent cells. These methods can be used to produced improved foregut- and hindgut-derived organoids containing enriched mesenchyme, which enhances organoid viability, growth, and maturation, both in in vitro culture and in vivo transplantation.

The present disclosure provides, among other things, a method of isolating and expanding gamma delta (γδ) T cells, wherein the method comprises: (a) isolating non-hematopoeitic tissue by biopsy or explant, and (b) culturing the isolated non-hematopoeitic tissue in the absence of a three-dimensional scaffold or grid, thereby expanding and isolating gamma delta (γδ) T cells.

Certain emboidments provide a method of promoting regeneration of one or more intestinal stem cells in a mammalian organoid culture, the method comprising treating the organoid culture with an effective amount of transforming growth factor beta (TGFB). Certain embodiments also provide a method for preparing an organoid culture comprising intestinal stem cells and a method of treating a subject with damaged or defective intestinal tissue comprising engrafting an organoid into the subject.

The present invention relates to a method for identifying a compound that modulates the mitotic cell cycle in cancer cells by modulating at least one of the expression, the amount, the stability and / or the biological activity of the protein CITED2 and / or CITED2 containing protein complexes in a mammalian cell. Further provided is a method for determining the level of CITED2 and / or CDK11bp58 and / or splicing factor 3B subunit 1 (SF3B1), and / or 14-3-3γ in a sample obtained from a subject, comprising detecting of binding of CITED2 in the sample to at least one molecule selected from the group consisting of CDK11bp58, splicing factor 3B subunit 1 (SF3B1), and 14-3-3γ, wherein a decrease of the binding, when compared to a control indicates an improper centrosome segregation and subsequent an increase of the formation of chaotic monopolar mitotic spindles in said sample. Further provided are pharmaceutical compositions comprising the compound as identified for use in medicine, in particular for use in the prevention or treatment of a disease or condition caused by cancer.

The present disclosure relates to a method for two-dimensionally culturing an intestinal stem cell population in a chemically defined medium and a use thereof, and also relates to a method for differentiating the intestinal stem cell population into 2.5-dimensional intestinal epithelial cells and a use thereof.

The present disclosure relates to a stem cell-drug carrier including a melatonin-containing drug carrier and a stem cell, and more particularly, to a use of the stem cell for the treatment of intestinal epithelial damage disease and inflammatory bowel disease. According to the present disclosure, it was confirmed that the stem cell-drug carrier continuously released PGE2 and had excellent revival stem cell induction ability. This means that the stem cell-drug carrier of the present disclosure has an excellent intestinal epithelium regeneration effect, and the stem cell-drug carrier of the present disclosure can be used in various fields of treatment of intestinal damage disease and inflammatory bowel disease.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

The invention discloses a recombinant oncolytic influenza virus for delivering an anti-gpA33 * CD3 bispecific antibody and application of the recombinant oncolytic influenza virus. Belongs to the technical field of biological medicine. According to the recombinant oncolytic influenza virus provided by the invention, a heavy chain variable region and a light chain variable region of an anti-gpA33 antibody and an anti-CD3 antibody are inserted into an influenza virus genome, the recombinant oncolytic influenza virus is rescued through a reverse genetics technology, and the virus can stably express an anti-gpA33 * CD3 bispecific antibody in colorectal cancer cells; one end of the antibody can be specifically combined with CD3 molecules on the surfaces of the T cells to efficiently activate the T cells, the other end of the antibody can be specifically combined with biomarker molecules gpA33 on the surfaces of the colorectal cancer cells, and under the bridging action of the antibody, the activated T cells are collected to the surfaces of the colorectal cancer cells to induce the T cells to directly generate the effect of targeted killing of the colorectal cancer cells, so that the colorectal cancer cells are efficiently killed. Therefore, the purpose of treating tumors is achieved.

This invention relates to the field of gastric cancer organoid microarray technology, and more particularly to a gastric cancer organoid microarray culture medium and its applications. The invention provides a novel culture medium adapted for gastric cancer organoid microarray culture. The medium components include basal medium, penicillin / streptomycin dual antibiotics, antibacterial agents, hydroxyethylpiperazine ethanesulfonic acid, B-27 additive, Glutamax culture medium additive, R-vertebral protein 1, scutellarin B, and tetramethylpyrazine, among other components. This invention solves key problems in existing technologies such as slow growth, morphological instability, poor heterogeneity adaptation, and low long-term culture activity of gastric cancer organoids, providing an ideal experimental model for high-throughput screening and precision medicine applications on microarrays.

The present application relates to the field of biotechnology, and particularly relates to a composition, a culture medium and application thereof in intestinal organoid culture. The present application first applies glucosamine hydrochloride to the culture of intestinal organoids, which can effectively promote organ proliferation and differentiation, and significantly increase the number of organ formation. On this basis, the present application constructs a three-dimensional culture system for postpartum neonatal, childhood and adult stages, and realizes the precise construction of mouse intestinal organoids at different development stages by combining dynamic regulation of extracellular matrix and optimization of growth factor combinations, thereby providing an in-vitro model covering multiple time sequences for intestinal development mechanism research and disease modeling.

The present application relates to a culture medium for the culture of intestinal organoids characterized in that it comprises neuregulin 1 (NRG1) and all-trans retinoic acid (atRA). It also relates to a method using this medium to culture intestinal organoids.

Provided is a method for designing organ-on-chips (OoCs) based on similarity principle, including determining a scaling ratio to obtain geometric dimensions of cell culture region of OoC; selecting dimensionless number as parameter calculation basis of the OoC, and calculating a range of corresponding in-vivo dimensionless number; acquiring flow rate range of fluid and size range of channels in OoC based on shear stress on cells in organ and calculated range of the dimensionless number; calculating characteristic lengths of channels according to the scaling ratio and determining corresponding flow rate; determining outer wall thickness of OoC based on oxygen permeability of material used for the OoC; performing simulation to verify whether all parameter indicators of OoC meet design requirements, and making mold sets according to outputted size design parameters for preparing the OoC; and, performing PDMS casting, curing, demolding, and bonding by using the mold sets to obtain the finished OoC.

This invention proposes a method for evaluating drug enterotoxicity in vitro using an intestinal organoid model, relating to the biomedical field. The method includes: preparing six different culture media and culturing hESCs in these media to induce directed endoderm cell differentiation, hindgut bulb differentiation, intestinal organoid differentiation, and intestinal organoid maturation, respectively. The resulting intestinal organoid model is then used to evaluate drug enterotoxicity. The intestinal organoid model prepared by this invention has a composition similar to human intestinal cells, accurately reflecting the toxic effects of drugs in the human physiological environment, while also allowing for large-scale reproducibility, avoiding clinical risks and ethical constraints. Furthermore, it can reflect the sensitivity to different enterotoxic drugs through cell viability, making it suitable for rapid, high-throughput in vitro evaluation of drug enterotoxicity.

The present invention relates to a method for expanding immune cells, comprising co-culturing the immune cells with at least one epithelial organoid, wherein the epithelial organoid comprises more epithelial cells than mesenchymal cells. The immune cells obtained by this method are at least 5×10 3 Also provided are in vitro innate lymphoid cell (ILC) populations comprising 100 ILCs, pharmaceutical compositions and uses thereof.

The invention relates to a preparation method and application of acellular extracellular matrix hydrogel for organoid culture, and the method comprises the following steps: step (1): preparing a small intestine acellular scaffold: sequentially putting pig small intestines without adipose tissues into a first solution, a second solution, a third solution and a fourth solution, stirring, and freezing and freeze-drying to obtain the small intestine acellular scaffold; step (2): preparing small intestine acellular matrix hydrogel, cutting a small intestine acellular scaffold into small pieces or grinding the small intestine acellular scaffold into powder, preparing a small intestine acellular scaffold solution with a hydrochloric acid solution and a pepsase solution, centrifuging, adding a PBS solution to terminate digestion, and adjusting the pH value to 6.0-8.0 to obtain solution state small intestine acellular matrix hydrogel; and gelling the solution-state small intestine extracellular matrix hydrogel at the temperature of 37 DEG C for 20-60 minutes to obtain the gel-state small intestine extracellular matrix hydrogel which is used for culturing alimentary canal organs.

The invention discloses a pig jejunum crypt separation and organoid model construction method, and belongs to the technical field of animal tissue separation and culture. The method specifically comprises the following steps: intestinal tract collection, cleaning solution preparation, intestinal tract treatment, tissue trimming, tissue cleaning, digestive juice preparation, tissue digestion, cell mass separation, crypt separation, crypt counting, crypt collection, crypt inoculation and organoid culture. The porcine jejunum organ obtained by the method has a typical three-dimensional cystic structure, has complete epithelial polar and functional cell types, including microvillus, goblet cells, panning cells and endocrine cells, and shows good barrier function and drug metabolic activity. A reliable in-vitro model platform is provided for pig intestinal development, nutrient absorption, pathogen infection mechanism research and precision medical treatment, meanwhile, a technical foundation is laid for large-scale application of organoids, and the method has important scientific significance and clinical value.

Provided herein are compositions of anorectal transition zone stem cells, including multipotent and progenitor cells, to treat damaged or dysfunctional ectodermal tissue. Also provided are cellular compositions of the anorectal transition zone stem cells, including multipotent and progenitor cells, in a pharmaceutically acceptable carrier.

The invention discloses a culture medium and a culture method for culturing a colorectal cancer ovarian metastasis micro-tumor model. The invention provides a culture medium for culturing a colorectal cancer ovarian metastasis micro-tumor model, and further provides a method for culturing the colorectal cancer ovarian metastasis micro-tumor model by using the culture medium. The colorectal cancer ovarian metastasis micro-tumor model obtained by the method can accurately reflect various characteristics of ovarian metastasis focuses of a patient, and is a good scientific research experiment model and a preclinical experiment model in the field of precise tumor diagnosis and treatment. It can be foreseen that the culture method has a wide application prospect in the fields of research and clinical diagnosis and treatment of colorectal cancer.

The invention discloses a construction method of a colorectal tumor model based on 3D printing, which comprises the following steps: dissolving methacrylated gelatin and phenyl (2, 4, 6-trimethylbenzoyl) lithium phosphate together to obtain a mixed solution, adding colorectal cancer cells HCT-116 and human skin fibroblasts BJ into the mixed solution, and uniformly mixing to obtain bio-ink; and loading the bio-ink into a charging barrel of an extrusion type biological 3D printer for 3D printing to obtain the tumor cell-carrying gel microspheres, and culturing in vitro to obtain the tumor cell-carrying gel microspheres. According to the method, the upper limit of cell density of liquid drop biological 3D printing is broken through, stable printing of biological ink with the cell density as high as 1 * 10 < 8 > cells / mL is successfully achieved through optimization of a rheological window, the density is close to the physiological level of solid tumors, the printed tumor model can truly simulate the high compactness of the tumors and the nutrition / oxygen gradient effect caused by the high compactness of the tumors, and the tumor model has good application prospects. And an experimental platform closer to the in vivo is provided for researching the microenvironment heterogeneity in the tumor.